FGFR2 Fusion

Loading variant…

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Bladder Carcinoma1
FGFR2::v Fusion	Erdafitinib	Predictive	A	Supports Sensitivity Response	4	submitted	EID11257 In this open-label, phase II trial, 99 patients with locally advanced and unresectable or metastatic urothelial carcinoma with various FGFR alterations who had a history of disease progression during … (full text at CIViC) PMID 31340094 · Loriot et al., 2019 · Open in CIViC	civic
Cholangiocarcinoma7
FGFR2::v Fusion	Derazantinib	Predictive	D	Supports Sensitivity Response	4	submitted	EID7969 ARQ 087 exhibited inhibitory effects biochemically, in cell line and cell cycle study of FGFR2 functions. PMID 27627808 · Hall et al., 2016 · Open in CIViC

Molecular profile

Therapy

Type

Level

Direction · significance

Rating (1–5)

Status

Evidence

Source

Bladder Carcinoma1

FGFR2::v Fusion

Erdafitinib

Predictive

Supports Sensitivity Response

submitted

EID11257

In this open-label, phase II trial, 99 patients with locally advanced and unresectable or metastatic urothelial carcinoma with various FGFR alterations who had a history of disease progression during … (full text at CIViC)

PMID 31340094 · Loriot et al., 2019 · Open in CIViC

civic

Cholangiocarcinoma7

FGFR2::v Fusion

Derazantinib

Predictive

Supports Sensitivity Response

submitted

EID7969

ARQ 087 exhibited inhibitory effects biochemically, in cell line and cell cycle study of FGFR2 functions.

PMID 27627808 · Hall et al., 2016 · Open in CIViC

Cholangiolocellular Small Duct Intrahepatic Cholangiocarcinoma1
FGFR2::v Fusion OR FGFR2::? Fusion	Pemigatinib	Predictive	A	Supports Sensitivity Response	4	accepted	EID8173 In a multicentre, open-label, single-arm, phase 2 study (FIGHT-202), patients with disease progression following at least one previous treatment received a starting dose of 13·5 mg oral pemigatinib on… (full text at CIViC) PMID 32203698 · Abou-Alfa et al., 2020 · Open in CIViC	civic

Cholangiolocellular Small Duct Intrahepatic Cholangiocarcinoma1

FGFR2::v Fusion OR FGFR2::? Fusion

Pemigatinib

Predictive

Supports Sensitivity Response

accepted

EID8173

In a multicentre, open-label, single-arm, phase 2 study (FIGHT-202), patients with disease progression following at least one previous treatment received a starting dose of 13·5 mg oral pemigatinib on… (full text at CIViC)

PMID 32203698 · Abou-Alfa et al., 2020 · Open in CIViC

civic

Intrahepatic Cholangiocarcinoma3
FGFR2::v Fusion OR FGFR2::? Fusion	Derazantinib	Predictive	B	Supports Sensitivity Response	3	accepted	EID7329 Actionable fibroblast growth factor receptor 2 (FGFR2) fusions have been identified in intrahepatic cholangiocarcinomas (iCCA). Derazantinib, a multi-kinase inhibitor with potent pan-FGFR activity sho… (full text at CIViC) PMID 30420614 · Mazzaferro et al., 2019 · Open in CIViC	civic
FGFR2::v Fusion OR FGFR2::? Fusion	Futibatinib	Predictive	A	Supports Sensitivity Response	4	submitted	EID11609 In the phase 2 trial (NCT02052778), 103 patients (22-79 years of age) with unresectable or metastatic intrahepatic cholangiocarcinoma harboring FGFR2 fusions or rearrangements were treated with the … (full text at CIViC) PMID 36652354 · Goyal et al., 2023 · Open in CIViC	civic
FGFR2::v Fusion OR FGFR2::? Fusion	Futibatinib	Predictive	B	Supports Sensitivity Response	3	submitted	EID11612 In a phase 2 trial (NCT02052778) of the FGFR1/2/3/4 inhibitor futibatinib in 103 patients with previously treated intrahepatic cholangiocarcinoma harboring FGFR2 fusions or rearrangements, the overal… (full text at CIViC) PMID 36652354 · Goyal et al., 2023 · Open in CIViC	civic

Intrahepatic Cholangiocarcinoma3

FGFR2::v Fusion OR FGFR2::? Fusion

Derazantinib

Predictive

Supports Sensitivity Response

accepted

EID7329

Actionable fibroblast growth factor receptor 2 (FGFR2) fusions have been identified in intrahepatic cholangiocarcinomas (iCCA). Derazantinib, a multi-kinase inhibitor with potent pan-FGFR activity sho… (full text at CIViC)

PMID 30420614 · Mazzaferro et al., 2019 · Open in CIViC

civic

FGFR2::v Fusion OR FGFR2::? Fusion

Futibatinib

Predictive

Supports Sensitivity Response

submitted

EID11609

In the phase 2 trial (NCT02052778), 103 patients (22-79 years of age) with unresectable or metastatic intrahepatic cholangiocarcinoma harboring FGFR2 fusions or rearrangements were treated with the … (full text at CIViC)

PMID 36652354 · Goyal et al., 2023 · Open in CIViC

civic

FGFR2::v Fusion OR FGFR2::? Fusion

Futibatinib

Predictive

Supports Sensitivity Response

submitted

EID11612

In a phase 2 trial (NCT02052778) of the FGFR1/2/3/4 inhibitor futibatinib in 103 patients with previously treated intrahepatic cholangiocarcinoma harboring FGFR2 fusions or rearrangements, the overal… (full text at CIViC)

PMID 36652354 · Goyal et al., 2023 · Open in CIViC

civic

Malignant Neoplasm1
FGFR2::v Fusion	Erdafitinib	Predictive	B	Supports Sensitivity Response	3	accepted	EID1918 Phase 1 study of pan-FGFR inhibitor JNJ-42756493 in patients with solid tumors. No responses were seen 36 patients without FGFR pathway aberrations. Among 23 patients with FGFR pathway aberrations, 4 … (full text at CIViC) PMID 26324363 · Tabernero et al., 2015 · Open in CIViC	civic

Malignant Neoplasm1

FGFR2::v Fusion

Erdafitinib

Predictive

Supports Sensitivity Response

accepted

EID1918

Phase 1 study of pan-FGFR inhibitor JNJ-42756493 in patients with solid tumors. No responses were seen 36 patients without FGFR pathway aberrations. Among 23 patients with FGFR pathway aberrations, 4 … (full text at CIViC)

PMID 26324363 · Tabernero et al., 2015 · Open in CIViC

civic

Multinodular and Vacuolated Neuronal Tumor1
BRAF Mutation OR FGFR2::v Fusion OR MAP2K1 Mutation	(diagnostic)	Diagnostic	C	Supports Positive	3	submitted	EID12458 Eight MVNT cases (6 pure MVNT and 2 with ganglioglioma-like features) were examined, comprising 4 males and 4 females aged 11–63 years (median 39). Tumors were localized to the temporal lobe (n=7) or … (full text at CIViC) PMID 29428973 · Pekmezci et al., 2018 · Open in CIViC	civic

Multinodular and Vacuolated Neuronal Tumor1

BRAF Mutation OR FGFR2::v Fusion OR MAP2K1 Mutation

(diagnostic)

Diagnostic

Supports Positive

submitted

EID12458

Eight MVNT cases (6 pure MVNT and 2 with ganglioglioma-like features) were examined, comprising 4 males and 4 females aged 11–63 years (median 39). Tumors were localized to the temporal lobe (n=7) or … (full text at CIViC)

PMID 29428973 · Pekmezci et al., 2018 · Open in CIViC

civic

Transitional Cell Carcinoma2
FGFR2 Mutation OR FGFR2::v Fusion OR FGFR2::? Fusion	Erdafitinib	Predictive	A	Supports Sensitivity Response	4	accepted	EID7261 Patients with metastatic or unresectable urothelial carcinoma havoring FGFR2 fusion, FGFR3 fusion or FGFR3 mutation were treated with pan-FGFR inhibitor, erdafitinib, in Phase 2 trial. 96 patients wer… (full text at CIViC) Open in CIViC	civic
FGFR2::v Fusion	Erdafitinib	Predictive	A	Supports Sensitivity Response	3	submitted	EID7423 In a phase 2 trial, patients with locally advanced and unresectable or metastatic urothelial carcinoma harboring FGFR3 mutation or FGFR2/3 fusion were treated with Erdafitinib. All the patients had a … (full text at CIViC) PMID 31340094 · Loriot et al., 2019 · Open in CIViC	civic

Transitional Cell Carcinoma2

FGFR2 Mutation OR FGFR2::v Fusion OR FGFR2::? Fusion

Erdafitinib

Predictive

Supports Sensitivity Response

accepted

EID7261

Patients with metastatic or unresectable urothelial carcinoma havoring FGFR2 fusion, FGFR3 fusion or FGFR3 mutation were treated with pan-FGFR inhibitor, erdafitinib, in Phase 2 trial. 96 patients wer… (full text at CIViC)

Open in CIViC

civic

FGFR2::v Fusion

Erdafitinib

Predictive

Supports Sensitivity Response

submitted

EID7423

In a phase 2 trial, patients with locally advanced and unresectable or metastatic urothelial carcinoma harboring FGFR3 mutation or FGFR2/3 fusion were treated with Erdafitinib. All the patients had a … (full text at CIViC)

PMID 31340094 · Loriot et al., 2019 · Open in CIViC

civic

Evidence by cancer (16 items)

Clinical significance (0)